Understanding What to Expect on 7.5 mg Mounjaro for Type 2 Diabetes and Weight Management
•
4 min read
Mounjaro (tirzepatide) is a groundbreaking dual GIP and GLP-1 receptor agonist, with clinical trials showing people can achieve an average weight loss of around 9% of their body weight after three months on the 7.5 mg dose. Moving up to this dose is a key part of the titration process for individuals managing type 2 diabetes and/or pursuing weight loss, requiring careful consideration of both its increased benefits and potential side effects.
